Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | APEX1 | P27695 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314687 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL9609762 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL5447002 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL6413992 | 0.99 | HSD17B10 (0.63) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL6904003 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL1603497 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL1044825 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL1603306 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL1603442 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB | |
| SCHEMBL1603028 | 0.98 | HSD17B10 (0.62) | HSD17B10TDP1MEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000779-A1 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-01-04 | — | — | US | claimed |
| EP-3840737-A1 | COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS COMPRISING THEM | MannKind Corporation (US) | 2021-06-30 | — | — | EP | claimed |
| CN-112804993-A | Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them | 曼金德公司 | 2021-05-14 | — | — | CN | claimed |
| WO-2020123336-A1 | COMPOSITIONS OF BEDAQUILINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS OF TREATMENT COMPRISING THEM | QRUMPHARMA INC. (US) | 2020-06-18 | — | — | WO | claimed |
| WO-2020040818-A1 | COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS COMPRISING THEM | QRUMPHARMA INC. (US) | 2020-02-27 | — | — | WO | claimed |
| WO-2019110099-A1 | INHALABLE CLOFAZIMINE FORMULATION | QRUMPHARMA INC. (US) | 2019-06-13 | — | — | WO | claimed |
| WO-2024054451-A1 | METHOD FOR TREATING NONTUBERCULOUS MYCOBACTERIAL INFECTION | HOFMANN THOMAS (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20240000779-A1 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2024-01-04 | — | — | US | disclosed |
| US-11793808-B2 | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them | MANNKIND CORP. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4054524-A1 | COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS OF TREATMENT COMPRISING THEM | MannKind Corporation (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114828828-A | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses comprising them and methods of treatment | 曼金德公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20220023282-A1 | Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | MANNKIND CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3840737-A1 | COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS COMPRISING THEM | MannKind Corporation (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112804993-A | Compositions containing clofazimine, combinations containing them, processes for their preparation, uses and processes containing them | 曼金德公司 | 2021-05-14 | — | — | CN | disclosed |
| WO-2020123336-A1 | COMPOSITIONS OF BEDAQUILINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS OF TREATMENT COMPRISING THEM | QRUMPHARMA INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020040818-A1 | COMPOSITIONS OF CLOFAZIMINE, COMBINATIONS COMPRISING THEM, PROCESSES FOR THEIR PREPARATION, USES AND METHODS COMPRISING THEM | QRUMPHARMA INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019110099-A1 | INHALABLE CLOFAZIMINE FORMULATION | QRUMPHARMA INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000779-A1 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | IL5, CYP3A5, CHRM5 | HSD17B10 2701/4885TDP1 4351/4885MEN1 2307/4885 |
| US-20220023282-A1 | Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | NDUFA7, UQCRB, NDUFS7 | HSD17B10 2225/4885TDP1 3277/4885MEN1 2867/4885 |
| US-11793808-B2 | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them | IL5, CYP3A5, CHRM5 | HSD17B10 2701/4885TDP1 4351/4885MEN1 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.